Aflac Shares Rise 1.07% on Morgan Stanley Upgrade Daily Volume Ranks 408th in Market Activity

On August 19, 2025, Aflac (AFL) saw a 1.07% rise in share price with a trading volume of $0.24 billion, ranking it 408th in market activity. The insurer’s performance drew attention following an upgraded price target from Morgan Stanley, reflecting renewed investor confidence in its core operations.

Morgan Stanley analyst Bob Huang raised the price target for Aflac to $113 from $108, maintaining an Equal Weight rating. This adjustment followed Q2 results that highlighted strong performance in the life insurance sector, where nearly half of covered insurers exceeded expectations. The firm attributed the earnings strength to selective underwriting strategies and robust results in macro-sensitive segments, signaling resilience amid market challenges.

Aflac operates through two primary segments: Aflac Japan and Aflac U.S., offering cancer, disability, and life insurance products. Its business model relies on independent agencies and corporate partnerships to distribute policies across both domestic and international markets. The company’s long-standing focus on supplemental coverage has positioned it to capitalize on sustained demand for risk management solutions.

The strategy of purchasing the top 500 stocks by daily trading volume and holding them for one day from 2022 to the present delivered a total return of 31.52% over 365 days, with an average 1-day return of 0.98%. This suggests the approach captured short-term momentum but remained subject to broader market volatility and timing risks.